Sustained Release of Exendin 4 Using Injectable and Ionic-Nano-Complex Forming Polymer Hydrogel System for Long-Term Treatment of Type 2 Diabetes Mellitus
Source abstract
Abstract
Daily treatment of diabetes to stabilize blood glucose level poses a challenge for patients with diabetes mellitus. Diabetes is a long-term metabolic disorder, and the treatment lasts for the rest of the patient's life after diagnosis. We presented a new injectable hydrogel depot system using exendin 4 (Ex-4) interactive and complex forming polymeric ionic-nano-particles for long-term antidiabetes treatment. Protamine-conjugated polymer (ProCP) was developed to form ionic-nano-complexes with Ex-4, as the amino-group-rich protamine and the negatively charged Ex-4 ( pI: 4.86) interact with each other due to their opposite electric charges in physiological conditions. Morphologically, the ProCP were nanoparticles in aqueous condition (10 wt % of ProCP in phosphate-buffered solution, <25 °C) and formed condensed ionic- and nano-complexes with Ex-4. The complexes formed a bulk hydrogel when exposed to body temperature. A slow release of the Ex-4/ProCP ionic-nano-complexes occurred from the hydrogel depot, followed by Ex-4 dissociation from the ionic-nano-complexes and hydrolysis of ProCP. Given that the Ex-4 release occurs after the complex releases from the hydrogel, the periods of Ex-4 release and hydrogel maintenance may be similar. The present system showed a considerably prolonged Ex-4 release. Additionally, it showed potential as a long-term effective and reproducible antidiabetes treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Diabetes Management and Research · Hydrogels: synthesis, properties, applications · Hyperglycemia and glycemic control in critically ill and hospitalized patients
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Center for Biomaterials, Korea Institute of Science & Technology, Seoul 130-650, Republic of Korea
Funding
Korea Institute of Science and Technology · National Research Foundation of Korea
References (32)
Show source-provided references
1. 10.1016/j.addr.2017.01.00610.1016/j.addr.2017.01.006 ↗
2. 10.2337/dc06-991210.2337/dc06-9912 ↗
3. 10.3810/pgm.2011.01.224110.3810/pgm.2011.01.2241 ↗
4. Bond, A. In Exenatide (Byetta) as a Novel Treatment Option for Type 2 Diabetes Mellitus, Baylor University Medical Center Proceedings, 2006; pp 281–284.10.1080/08998280.2006.11928181 ↗
5. 10.3109/03639045.2015.110709010.3109/03639045.2015.1107090 ↗
6. 10.7326/0003-4819-143-8-200510180-0000610.7326/0003-4819-143-8-200510180-00006 ↗
7. 10.1016/j.biomaterials.2010.01.09110.1016/j.biomaterials.2010.01.091 ↗
8. 10.1345/aph.1Q72210.1345/aph.1Q722 ↗
9. 10.1021/acs.jmedchem.5b0072610.1021/acs.jmedchem.5b00726 ↗
10. 10.1021/acs.biomac.5b0175610.1021/acs.biomac.5b01756 ↗
11. 10.1016/j.ejpb.2009.02.00110.1016/j.ejpb.2009.02.001 ↗
12. 10.7150/thno.1022610.7150/thno.10226 ↗
13. 10.1248/bpb.b12-0002910.1248/bpb.b12-00029 ↗
14. 10.1021/bc300265n10.1021/bc300265n ↗
15. 10.1111/j.1464-5491.2012.03745.x10.1111/j.1464-5491.2012.03745.x ↗
16. 10.1089/dia.2011.005010.1089/dia.2011.0050 ↗
17. 10.1021/acs.molpharmaceut.8b0034410.1021/acs.molpharmaceut.8b00344 ↗
18. 10.1016/j.jconrel.2014.09.01410.1016/j.jconrel.2014.09.014 ↗
19. 10.1016/j.actbio.2013.10.00910.1016/j.actbio.2013.10.009 ↗
20. 10.1016/j.biomaterials.2011.07.03310.1016/j.biomaterials.2011.07.033 ↗
21. 10.1016/j.jconrel.2015.04.02310.1016/j.jconrel.2015.04.023 ↗
22. 10.1016/j.biomaterials.2017.01.01610.1016/j.biomaterials.2017.01.016 ↗
23. 10.1016/j.ejpb.2004.03.00310.1016/j.ejpb.2004.03.003 ↗
24. 10.1016/j.ijpharm.2008.01.05710.1016/j.ijpharm.2008.01.057 ↗
25. 10.1021/nn300842a10.1021/nn300842a ↗
26. 10.1016/j.biomaterials.2009.10.02210.1016/j.biomaterials.2009.10.022 ↗
27. 10.1111/j.1742-1241.2010.02503.x10.1111/j.1742-1241.2010.02503.x ↗
28. 10.1021/ma00126a03910.1021/ma00126a039 ↗
29. 10.1021/la990946q10.1021/la990946q ↗
30. 10.1021/ed039pA217.210.1021/ed039pA217.2 ↗
31. 10.1016/j.biomaterials.2008.12.08310.1016/j.biomaterials.2008.12.083 ↗
32. 10.1016/j.ejpb.2006.01.00110.1016/j.ejpb.2006.01.001 ↗